John R. Mac Donald, PhD
About John R. Mac Donald, PhD
John R. MacDonald, PhD, is a seasoned pharmaceutical executive with over 30 years of experience in drug development, currently serving as the SVP of R&D and acting CEO of PepTx, Inc.
John R. MacDonald, PhD - SVP of R&D
John R. MacDonald serves as the Senior Vice President of Research and Development. With over 30 years of experience, he specializes in all aspects of pharmaceutical drug development and licensing. His extensive career has seen him lead significant pharmaceutical projects and provide consultancy services across various sectors of the drug development industry.
John R. MacDonald's Education and Expertise
John R. MacDonald earned his PhD in Pharmacology and Toxicology from the University of Arizona. His academic background has provided a robust foundation for his extensive career in pharmaceutical R&D, enabling him to make significant contributions to the field of drug development and licensing.
John R. MacDonald's Background in Pharmaceutical Industry
John R. MacDonald has held various pivotal roles in the pharmaceutical industry. At Warner-Lambert, now Pfizer, he gained invaluable experience in large pharma. Additionally, he served as a NIH funded researcher at UC San Francisco. His diverse background also includes leading preclinical and clinical R&D at MGI Pharma, focusing on oncology until 2005, and continued consulting after MGI's acquisition by Eisai in 2008.
Achievements and Roles at MGI Pharma and Beyond
From 1996 through 2005, John R. MacDonald led the preclinical and clinical R&D efforts at MGI Pharma, an oncology-centric company. Post-2008, he has remained active in drug development through his consultancy firm, Ridge Road Consulting. His consultancy roles include advising academic institutions, startups, and small pharma companies. He also serves as the acting CEO of PepTx, Inc., a University of Minnesota startup.
John R. MacDonald's Role at Ridge Road Consulting
John R. MacDonald is the founder of Ridge Road Consulting, where he continues to contribute to drug development. Through his consultancy, he advises academic institutions and small pharmaceutical companies, leveraging his extensive experience to guide them through the complexities of pharmaceutical R&D and licensing.